Navigation Links
Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
Date:11/7/2007

tion and other global regulatory agencies and incorporates the most current clinical trial standards and prevailing protocol design for smoking cessation studies. The trial's primary endpoint is the rate of carbon monoxide (CO)-confirmed, continuous abstinence from smoking during weeks 19-26 after first vaccination. In May 2007, Nabi announced this trial's six-month data, which showed that a statistically significant number of patients with in the high anti-nicotine antibody responder group met the trial's primary endpoint of eight weeks of continuous abstinence between weeks 19-26.

About NicVAX(R)

NicVAX(R) is an innovative and proprietary investigational vaccine being developed by Nabi to treat nicotine addiction and prevent smoking relapse. NicVAX(R) is designed to stimulate the immune system to produce antibodies that bind to nicotine. A nicotine molecule attached to an antibody is too large to cross the blood-brain barrier. Therefore, NicVAX(R) blocks nicotine from reaching its receptors in the brain and prevents the highly-addictive pleasure sensation experienced by smokers and users of nicotine products. Pre-clinical and previous clinical data, as well as the study reported here, show that NicVAX(R)'s ability to block nicotine from reaching the brain could help people quit smoking. Because the body's immune system can be boosted to produce long-lasting antibodies, Nabi believes NicVAX(R) also could be effective in preventing smoking relapse. Relapse is a significant challenge facing smokers and, with currently-available smoking cessation therapies, relapse rates can be as high as 90% in the first year after a smoker quits.

NicVAX(R) Development Progress to Date

In September 2005, Nabi announced that it received a $4.1 million grant from the National Institute on Drug Abuse (NIDA), which is part of the National Institutes of Health. NIDA has also funded, in part, the costs for toxicology testing and earlier clinical trials in the U.S. a
'/>"/>

SOURCE Nabi Biopharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... With advancements in neurological and functional ... seeing new growth, according to Kalorama Information. Though ... the majority of market volume, newer 3T systems ... are creating opportunities for more sophisticated applications. The medical ... a rate of 4%, with world market revenues ...
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
(Date:12/15/2014)... and Markets ( http://www.researchandmarkets.com/research/bf3b6l/electrocardiogram ) has announced ... Global Trends, Estimates and Forecasts, 2012-2018" report to ... Global Electrocardiogram Devices (ECG) sector is projected ... North America accounts for nearly 36% (2015) ... claims approximately 27% (2018). Asia-Pacific ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... , FREMONT, Calif. , March 11 Lorom West, a premier manufacturer of custom cables, wire harnesses, PCB and high quality OEM/ODM products today announced successful certification ... ... ... ...
... March 11 Zimmer Holdings, Inc. (NYSE: ... showcased its recently introduced Continuum Acetabular Cup System ...  The Continuum Cup combines ... Metal™ Technology, Metasul ® Metal-on-Metal technology, BIOLOX ...
Cached Medicine Technology:Lorom West Announces Successful Certification to the ISO 13485: 2003 Quality Management Standard (QMS) for Medical Devices 2Lorom West Announces Successful Certification to the ISO 13485: 2003 Quality Management Standard (QMS) for Medical Devices 3New Hip Implant Provides Personalized Fit 2New Hip Implant Provides Personalized Fit 3New Hip Implant Provides Personalized Fit 4
(Date:12/17/2014)... (HealthDay News) -- Poor students get more fruits and vegetables ... finds. But, the opposite is true for students from ... vegetables at school may give a healthy boost to poor ... what the family income level, students all ate a similar ... The study was published recently in the journal ...
(Date:12/15/2014)... Grants Pass, OR (PRWEB) December 15, 2014 ... factors perceived by United States women as impacting skin ... – the “Four C’s of skin care.” Water and ... the conclusions in a recent article describing the survey ... her experience, every item in every category discussed would ...
(Date:12/15/2014)... SIMpalm, a leading mobile app development company , ... client, which allows users to keep track of wines ... the right wine. At the center of WineMatch ... and wine information. All this information is assembled to ... that are close counterparts to one another are called ...
(Date:12/15/2014)... Dallas,TX (PRWEB) December 15, 2014 The increase ... is one of the main factors which is contributing to ... used for the diagnosis and treatment of hearing loss and ... comprises of three parts - microphone, speaker and amplifier. The ... growth rate of 6.01% during the period from 2014 to ...
(Date:12/15/2014)... Toronto, Ontario (PRWEB) December 15, 2014 Bacteroides ... indoors. Not only is it much more prevalent than coliforms, ... not replicate in the environment. , Key Benefits of ... results for fecal contamination , Eliminates false positives ... Higher Specificity and Sensitivity , Maintain the ...
Breaking Medicine News(10 mins):Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
... are developing the first device able to transmit American ... just completing its initial field test by participants in ... "This is the first study of how deaf people ... project leader Eve Riskin, a UW professor of electrical ...
... MONDAY, Aug. 16 (HealthDay News) -- Folks with Internet connections ... folks without access to the Web, a new study shows. ... the old standby, "friends," as the number one way to ... at the American Sociological Association annual meeting in Atlanta. ...
... with cancer progression when abundant inside of tumors also ... feed the tumor outside, a research team led by ... Center reports in the August edition of Cancer ... block production of the protein, the researchers inhibited formation ...
... University have won federal support to develop a genomic test ... by a natural pathogen or one that was grown in ... first from the Defense Threat Reduction Agency -- is designed ... tools they need to quickly determine how to respond to ...
... Mount Sinai School of Medicine have for the first ... vulnerable to rupture using multi-color computed tomography (CT), an ... of cardiovascular disease. The data are published in the ... atherosclerotic plaques are the cause of nearly 70 percent ...
... The Donor Risk Index, which assesses donor characteristics impacting liver ... on a small scale as is suggested from large-scale, national ... to be the major contributor to poor graft survival in ... The goals of the study were to confirm the effect ...
Cached Medicine News:Health News:Deaf, hard-of-hearing students perform first test of sign language by cell phone 2Health News:Deaf, hard-of-hearing students perform first test of sign language by cell phone 3Health News:Web Connection Raises Chances of Romance 2Health News:Web Connection Raises Chances of Romance 3Health News:Novel role: EZH2 boosts creation of ovarian cancer blood vessels 2Health News:Novel role: EZH2 boosts creation of ovarian cancer blood vessels 3Health News:Telltale signs of bioterror 2Health News:Mount Sinai pioneers new cardiac imaging device 2Health News:Henry Ford Hospital study: Donor Risk Index does not impact outcomes on a small scale 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: